Dianthus Therapeutics, Inc., was incorporated under the laws of the State of Delaware on June 17, 2015. The company is a clinical-stage biotechnology company that develops new drugs to bring the therapeutic capabilities of bone marrow transplantation to more patients. The company intends to become a fully integrated discovery, development and commercial company in the field of transplant medicine. The company believes that the product portfolio will provide significant commercial synergies. The company is developing products so that they can be used alone or in combination with each other. Therefore, the company's portfolio can be used in a manner appropriate to the patient's disease so that patients can receive more than one magenta therapy as part of their personal transplant journey.